FNAM (Evolutionary Genomics) Future 3-5Y EPS without NRI Growth Rate : N/A (As of Sep. 23, 2024)

View and export this data going back to 2011. Start your Free Trial

What is Evolutionary Genomics Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Evolutionary Genomics's Future 3-5Y EPS without NRI Growth Rate is N/A.

Competitive Comparison of Evolutionary Genomics's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Evolutionary Genomics's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evolutionary Genomics's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Evolutionary Genomics's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Evolutionary Genomics's Future 3-5Y EPS without NRI Growth Rate falls into.

Evolutionary Genomics (OTCPK:FNAM) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Evolutionary Genomics Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Evolutionary Genomics's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Evolutionary Genomics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Evolutionary Genomics Inc (OTCPK:FNAM) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

4220 Morning Star Drive, Castle Rock, CO, USA, 80108

Website

https://www.evolgen.com

Evolutionary Genomics Inc is involved in the development of a technology platform, the Adapted Traits Platform (ATP), to identify commercially valuable genes that control important traits in animals and plants. It uses the ATP to identify genes to improve crop plant traits such as yield, sugar content, biomass, drought tolerance, and pest/disease resistance. The company's platform identifies key genes that have changed successfully to impart new or improved traits. Its primary source of revenue had been contract services revenue for research performed by it on behalf of other commercial entities and grant income received from governmental agencies, industry associations and grant-making foundations for research performed.

Executives

Steve B Warnecke	director, 10 percent owner, officer: Chairman, CEO	C/O TARGETED MEDICAL PHARMA, INC., 2980 BEVERLY GLEN CIRCLE, SUITE 301, LOS ANGELES CA 90077
Virginia P. Orndorff	director	4580 AUGUSTA DR., BROOMFIELD CO 80023
Walter Messier	officer: Secretary / Treasurer	1586 GOSHAWK DRIVE, LONGMONT CO 80504
Mark Virgil Boggess	director	7857 E OAKBROOK CIR, MADISON WI 53717
Sanford Schwartz	director, 10 percent owner	5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Michael Friess	director, 10 percent owner, officer: President/CEO	5353 MANHATTAN CIRCLE, STE 101, BOULDER CO 80303
Chloe M Divita	director, officer: Secretary/Treasurer/CFO	5353 MANHATTAN CIRCLE, SUITE 101, BOULDER CO 80303

Evolutionary Genomics Headlines

No Headlines